Protagonist Therapeutics, Inc.
PTGX
$155.10
$3.682.43%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 34.81% | -64.36% | -89.41% | -35.39% | -34.45% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 34.81% | -64.36% | -89.41% | -35.39% | -34.45% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 34.81% | -64.36% | -89.41% | -35.39% | -34.45% |
| SG&A Expenses | 17.12% | 15.15% | 3.20% | -0.44% | 3.34% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 20.76% | 19.91% | 12.42% | 8.89% | 10.98% |
| Operating Income | 143.34% | -623.31% | -162.54% | -87.25% | -84.25% |
| Income Before Tax | 56.82% | -302.10% | -146.28% | -72.23% | -68.84% |
| Income Tax Expenses | -17.97% | -174.27% | -80.14% | -3.05% | -34.26% |
| Earnings from Continuing Operations | 59.32% | -304.14% | -147.29% | -73.13% | -69.38% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 59.32% | -304.14% | -147.29% | -73.13% | -69.38% |
| EBIT | 143.34% | -623.31% | -162.54% | -87.25% | -84.25% |
| EBITDA | 140.80% | -602.68% | -161.83% | -86.65% | -83.77% |
| EPS Basic | 44.58% | -302.10% | -145.57% | -72.97% | -69.75% |
| Normalized Basic EPS | 42.46% | -300.05% | -144.59% | -72.10% | -69.23% |
| EPS Diluted | 44.87% | -340.73% | -148.94% | -76.49% | -73.08% |
| Normalized Diluted EPS | 43.27% | -334.49% | -147.53% | -75.33% | -72.33% |
| Average Basic Shares Outstanding | 3.30% | 3.24% | 3.26% | 3.38% | 3.66% |
| Average Diluted Shares Outstanding | 5.75% | 3.71% | 0.48% | 3.30% | 3.57% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |